Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 6INDUSTRY 5

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 26Dermatologic 18Head & Neck 14Genitourinary 13Gastrointestinal 12Tumor-Agnostic 6Breast 6Sarcoma 5Lymphoid 5Gynecologic 4Other solid neoplasm 3Endocrine 3CNS 3Plasma cell 1Other hematologic neoplasm 1Other 1Myeloid 1

Conditions

Neoplasm Metastasis 4Neoplasms 2Carcinoma, Squamous Cell 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × cemiplimab × Tumor-Agnostic × Clear all
NCT07404332 2026-05-28

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

University of Iowa

Phase 1 Recruiting
35 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06790602 2026-04-09

SWITCH

University of California, San Diego

Phase 2 Recruiting
43 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT07346196 2026-01-20

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

University of Chicago

Phase 2 Not yet recruiting
90 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT04706715 2025-05-31

LAG3 PET Imaging in Advanced Solid Tumors

University Medical Center Groningen

Phase 1/2 Active not recruiting
41 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05878288 2024-11-21

DISCERN

Peter MacCallum Cancer Centre, Australia

Phase 2 Active not recruiting
11 enrolled
Tumor-Agnostic

Neoplasms

NCT04729725 2023-08-14

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

M.D. Anderson Cancer Center

Phase 1 Terminated
3 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡